Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $37.00 at Wedbush

Viridian Therapeutics (NASDAQ:VRDN) had its price objective decreased by Wedbush from $44.00 to $37.00 in a research report released on Tuesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other brokerages have also weighed in on VRDN. Royal Bank Of Canada cut their price objective on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. William Blair started coverage on shares of Viridian Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating for the company. Wall Street Zen downgraded shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, January 21st. Finally, Needham & Company LLC lowered their price objective on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a research note on Monday. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock opened at $19.56 on Tuesday. The stock has a fifty day moving average price of $29.16 and a 200 day moving average price of $27.89. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29. The firm has a market capitalization of $2.00 billion, a P/E ratio of -5.95 and a beta of 1.00. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. Equities research analysts anticipate that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. acquired a new position in Viridian Therapeutics during the third quarter valued at approximately $1,079,000. Hudson Bay Capital Management LP increased its position in shares of Viridian Therapeutics by 46.6% in the third quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock worth $3,782,000 after acquiring an additional 55,689 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Viridian Therapeutics by 135.6% in the third quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock worth $25,922,000 after acquiring an additional 691,267 shares in the last quarter. Propel Bio Management LLC purchased a new position in shares of Viridian Therapeutics in the 3rd quarter valued at $1,942,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Viridian Therapeutics by 430.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company’s stock valued at $1,394,000 after acquiring an additional 52,414 shares in the last quarter.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.